問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
姜乃榕
下載
2023-07-28 - 2023-11-13
Condition/Disease
Test Drug
Participate Sites5Sites
Recruiting1Sites
Terminated4Sites
2020-05-18 - 2023-12-31
Participate Sites6Sites
Recruiting6Sites
2025-02-03 - 2029-01-31
Recruiting5Sites
2024-04-10 - 2028-07-25
2025-05-31 - 2031-04-30
Participate Sites1Sites
2023-02-01 - 2027-06-30
Participate Sites4Sites
Recruiting4Sites
2018-10-01 - 2021-03-31
Recruiting3Sites
Terminated1Sites
未分科
2024-04-01 - 2028-01-31
Advanced/Metastatic Solid Tumors
injection
Participate Sites10Sites
Not yet recruiting1Sites
Recruiting8Sites
2019-02-01 - 2019-12-25
2018-10-01 - 2022-12-31
Nasopharyngeal Carcinoma
Pembrolizumab (MK3475)
Participate Sites8Sites
Terminated3Sites
全部
